Breaking News, Collaborations & Alliances

Isis, AstraZeneca In Antisense Therapies Alliance

To discover and develop therapies for cardiovascular, metabolic and renal diseases

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Isis Pharmaceuticals, Inc. and AstraZeneca entered a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. The collaboration expands an existing relationship to support AZ’s strategic approach in these therapeutic areas using novel RNA-targeted treatments. It also enables Isis to extend use of its antisense technology to diseases of the kidney. Isis will receive $65 million upfront plus development and regulatory milestones fo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters